Shenzhen TargetRx Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| TGRX-326 NCT05955391 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer | 164 | 2024-12-29 (+10 mo) |
| TGRX-814 NCT06206174 |
P1/2 | Recruiting | Hematologic Malignancy; Non Hodgkin Lymphoma | 30 | 2025-02-28 |
| TGRX-326 NCT06082635 |
P3 | Active, not recruiting | Non Small Cell Lung Cancer | 321 | 2026-04-30 (+16 mo) |
| TGRX-678 NCT06453902 |
P2 | Recruiting | Chronic Myeloid Leukemia; Accelerated Phase CML | 40 | 2026-06-30 |
| TGRX-678 NCT07489755 |
P3 | Not yet recruiting | Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia - Chronic Phase | 180 | 2030-05-01 |